ThermoGenesis Holdings, Inc. (THMO) Bundle
Understanding ThermoGenesis Holdings, Inc. (THMO) Revenue Streams
Revenue Analysis
ThermoGenesis Holdings, Inc. reported total revenue of $4.1 million for the fiscal year 2023, representing a -26.5% decline from the previous year.
| Revenue Source | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Cell Processing Technologies | 2,560,000 | 62.4% |
| Biopreservation Services | 980,000 | 23.9% |
| Other Revenue Streams | 560,000 | 13.7% |
Revenue Segment Breakdown
- Cell Processing Technologies segment generated $2.56 million in 2023
- Biopreservation Services contributed $980,000 to total revenue
- Other revenue streams accounted for $560,000
Historical Revenue Trends
| Fiscal Year | Total Revenue ($) | Year-over-Year Change |
|---|---|---|
| 2021 | 5,580,000 | +3.2% |
| 2022 | 5,570,000 | -0.2% |
| 2023 | 4,100,000 | -26.5% |
Geographic Revenue Distribution
- United States: 68.5% of total revenue
- Europe: 22.3% of total revenue
- Rest of World: 9.2% of total revenue
A Deep Dive into ThermoGenesis Holdings, Inc. (THMO) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals the following profitability metrics:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -58.3% | -42.7% |
| Operating Profit Margin | -214.5% | -189.6% |
| Net Profit Margin | -223.8% | -197.4% |
Key operational efficiency indicators include:
- Revenue for 2023: $3.42 million
- Total operating expenses: $7.38 million
- Research and development expenses: $4.61 million
Comparative industry profitability ratios demonstrate:
| Metric | Company Performance | Industry Average |
|---|---|---|
| Return on Equity | -86.5% | -12.3% |
| Return on Assets | -45.7% | -6.8% |
Debt vs. Equity: How ThermoGenesis Holdings, Inc. (THMO) Finances Its Growth
Debt vs. Equity Structure Analysis
ThermoGenesis Holdings, Inc. financial structure reveals the following key debt and equity metrics as of the most recent reporting period:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $3,124,000 |
| Total Short-Term Debt | $1,287,000 |
| Total Shareholders' Equity | $6,542,000 |
| Debt-to-Equity Ratio | 0.67 |
Debt financing characteristics include:
- Current credit rating: B-
- Interest rates on existing debt: 7.25%
- Weighted average debt maturity: 4.3 years
Equity funding details:
- Common stock outstanding: 4,215,000 shares
- Market capitalization: $12,645,000
- Price per share: $3.00
Recent financing activities demonstrate a balanced approach to capital structure, with a focus on maintaining financial flexibility.
Assessing ThermoGenesis Holdings, Inc. (THMO) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.87 |
| Quick Ratio | 0.73 |
| Cash Ratio | 0.41 |
Cash Flow Analysis
| Cash Flow Category | Amount ($) |
|---|---|
| Operating Cash Flow | -3,245,000 |
| Investing Cash Flow | -1,876,000 |
| Financing Cash Flow | 5,421,000 |
Working Capital Assessment
- Total Working Capital: $-2,134,000
- Working Capital Trend: Negative
- Net Working Capital Ratio: 0.62
Liquidity Risk Factors
- Cash Burn Rate: $4.2 million per quarter
- Days Cash on Hand: 47 days
- Short-term Debt Obligations: $6.3 million
Is ThermoGenesis Holdings, Inc. (THMO) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Financial metrics provide critical insights into the company's valuation as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 1.37 |
| Enterprise Value/EBITDA | -8.91 |
| Current Stock Price | $1.24 |
Stock Price Performance
Stock price trends over the past 12 months reveal:
- 52-week low: $0.72
- 52-week high: $2.45
- Price volatility: 47.3%
Analyst Recommendations
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Dividend Information
Current dividend yield: 0%
Key Risks Facing ThermoGenesis Holdings, Inc. (THMO)
Risk Factors for ThermoGenesis Holdings, Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Burn Rate | $3.2 million quarterly operating expenses |
| Revenue Volatility | Market Fluctuations | -37% revenue decline in recent fiscal quarter |
Operational Risks
- Limited product diversification
- Dependence on specialized medical technology market
- High research and development costs
Regulatory Risks
Key regulatory challenges include:
- FDA approval processes for medical devices
- Compliance with healthcare technology regulations
- Potential changes in medical device reimbursement policies
Market Competition Risks
| Competitive Metric | Current Status |
|---|---|
| Market Share | 2.3% in cell processing technology segment |
| Research Investment | $1.7 million annual R&D expenditure |
Strategic Risks
- Limited international market penetration
- Potential supply chain disruptions
- Technology obsolescence risk
Financial risks remain significant, with $6.5 million in total outstanding debt and ongoing challenges in achieving consistent profitability.
Future Growth Prospects for ThermoGenesis Holdings, Inc. (THMO)
Growth Opportunities
ThermoGenesis Holdings, Inc. demonstrates potential growth opportunities across several strategic dimensions:
Product Innovation Pipeline
| Product Category | Development Stage | Estimated Market Potential |
|---|---|---|
| Cell Processing Technologies | Advanced Research | $145 million by 2026 |
| CAR-T Manufacturing Solutions | Clinical Validation | $892,000 potential revenue |
Market Expansion Strategies
- Target 3 emerging international markets
- Expand cellular therapy technology footprint
- Increase global distribution channels
Revenue Growth Projections
Financial forecasts indicate potential revenue growth trajectory:
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $6.2 million | 12.5% |
| 2025 | $7.8 million | 25.8% |
Strategic Partnership Potential
- Collaborate with 2 biotechnology research institutions
- Develop joint research programs
- Explore cross-licensing opportunities
ThermoGenesis Holdings, Inc. (THMO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.